With your risk of Parkinsons post stroke, your competent? doctor and hospital should be ensuring that EXACT PROTOCOLS GET WRITTEN ON THIS! Or don't you have a competent doctor or hospital?
Parkinson’s Disease May Have Link to Stroke March 2017
The latest here:
Trial of Lixisenatide in Early Parkinson’s Disease
Abstract
Background
Lixisenatide,
a glucagon-like peptide-1 receptor agonist used for the treatment of
diabetes, has shown neuroprotective properties in a mouse model of
Parkinson’s disease.
Methods
In
this phase 2, double-blind, randomized, placebo-controlled trial, we
assessed the effect of lixisenatide on the progression of motor
disability in persons with Parkinson’s disease. Participants in whom
Parkinson’s disease was diagnosed less than 3 years earlier, who were
receiving a stable dose of medications to treat symptoms, and who did
not have motor complications were randomly assigned in a 1:1 ratio to
daily subcutaneous lixisenatide or placebo for 12 months, followed by a
2-month washout period. The primary end point was the change from
baseline in scores on the Movement Disorder Society–Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher
scores indicating greater motor disability), which was assessed in
patients in the on-medication state at 12 months. Secondary end points
included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of
levodopa equivalent.
Results
A
total of 156 persons were enrolled, with 78 assigned to each group.
MDS-UPDRS part III scores at baseline were approximately 15 in both
groups. At 12 months, scores on the MDS-UPDRS part III had changed by
−0.04 points (indicating improvement) in the lixisenatide group and 3.04
points (indicating worsening disability) in the placebo group
(difference, 3.08; 95% confidence interval, 0.86 to 5.30; P=0.007). At
14 months, after a 2-month washout period, the mean MDS-UPDRS motor
scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with
lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other
results relative to the secondary end points did not differ
substantially between the groups. Nausea occurred in 46% of participants
receiving lixisenatide, and vomiting occurred in 13%.
Conclusions
In
participants with early Parkinson’s disease, lixisenatide therapy
resulted in less progression of motor disability than placebo at 12
months in a phase 2 trial but was associated with gastrointestinal side
effects. Longer and larger trials are needed to determine the effects
and safety of lixisenatide in persons with Parkinson’s disease. (Funded
by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov
number, NCT03439943.)
No comments:
Post a Comment